<DOC>
	<DOCNO>NCT02093663</DOCNO>
	<brief_summary>To assess clinical response MMX mesalamine/mesalazine low high dose child adolescent age 5-17 year mild moderate Ulcerative Colitis ( UC ) remission .</brief_summary>
	<brief_title>Safety Efficacy MMX Mesalamine/Mesalazine Pediatric Subjects With Mild Moderate Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>1 . Ability voluntarily provide write , sign , date ( personally via legally authorize representative [ LAR ] ) inform consent assent applicable participate study . 2 . Subject 's parent/LAR demonstrate understanding , ability , willingness fully comply study procedure restriction . 3 . Male female child adolescent age 517 year , inclusive . 4 . Body weight 1890kg . 5 . Male , nonpregnant , nonlactating female agree comply applicable contraceptive requirement protocol female nonchildbearing potential . 6 . Diagnosed mild moderate UC , establish sigmoidoscopy colonoscopy compatible histology . Screened subject may also unconfirmed diagnosis mild moderate UC ; however diagnosis mild moderate UC must establish sigmoidoscopy colonoscopy compatible histology prior baseline visit . 7 . Subject able swallow investigational product whole . Doubleblind Acute Phase : 8 . Partial UCDAI score ≥2 ( combine rectal bleed stool frequency score ≥1 PGA=1 2 ) Baseline Visit , 5ASA would use part normal treatment . 9 . If subject 5ASA treatment prior study entry , dose must stable . Stable therapy define change dose , initiation 5ASA , onset current acute flare discontinuation therapy ( require Baseline Visit ) . Doubleblind Maintenance Phase : 10 . Partial UCDAI ≤1 ( rectal bleeding=0 , stool frequency ≤1 , PGA=0 ) Baseline Visit . 1 . Severe UC ( define PGA=3 ) . 2 . Crohn 's disease , bleed disorder , active peptic ulcer disease , UC know confine rectum ( isolated rectal proctitis ) . 3 . Asthma , know 5 ASA sensitive . 4 . Positive stool culture enteric pathogen ( include Salmonella , Shigella , Yersinia , Aeromonas , Plesiomonas , Campylobacter ) . Clostridium difficile toxin , ovum , parasites present . 5 . Systemic rectal corticosteroid use within 4 week prior Screening Visit . Topical , intranasal , inhale use exclusionary . 6 . Immunomodulator ( 6mercaptopurine , azathioprine ) use within 6 week prior Screening Visit . 7 . History biologic ( eg , antitumor necrosis factor agent , integrin receptor antagonist ) use time . 8 . Antibiotic use within 7 day prior Screening Visit . 9 . Any antiinflammatory drug , include 5ASA treatment include nonsteroidal antiinflammatory drug aspirin , COX2 inhibitor ibuprofen , within 7 day prior Screening Visit unless use overthecounter level &lt; 3 day . However , prophylactic use stable dose aspirin 325mg/day cardiac disease permit . 10 . Prebiotic/probiotic use within 7 day prior Screening Visit . Yogurt product permit .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mild</keyword>
	<keyword>Moderate</keyword>
</DOC>